Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Abiraterone

Cardiovascular risk factors with hormonal therapies in prostate cancer
2:41
Cardiovascular risk factors with hormonal therapies in prostate cancer
Dalia Kaakour • 4 Mar 2026
Prostate cancer at ASCO GU 2026: PEACE-3, BRCAAway, and T-cell engagers
1:24
Prostate cancer at ASCO GU 2026: PEACE-3, BRCAAway, and T-cell engagers
Tian Zhang • 3 Mar 2026
TulmiSTAR-02: tulmimetostat plus darolutamide or abiraterone in mHSPC
1:54
TulmiSTAR-02: tulmimetostat plus darolutamide or abiraterone in mHSPC
Neal Shore • 3 Mar 2026
Assessing darolutamide and ADT safety vs other ARPIs in mCSPC
1:36
Assessing darolutamide and ADT safety vs other ARPIs in mCSPC
Neal Shore • 28 Feb 2026
ARTO: long-term OS of SBRT and abiraterone in oligometastatic prostate cancer
0:48
ARTO: long-term OS of SBRT and abiraterone in oligometastatic prostate cancer
Giulio Francolini • 26 Feb 2026
Advances in mHSPC treatment strategies: PARP inhibitors, PSMA-targeting & more
1:44
Advances in mHSPC treatment strategies: PARP inhibitors, PSMA-targeting & more
Andrew Armstrong • 12 Jun 2025
CHAARTED2: CTC and AR-V7 analysis of abiraterone ± cabazitaxel in mCRPC
2:43
CHAARTED2: CTC and AR-V7 analysis of abiraterone ± cabazitaxel in mCRPC
Christos Kyriakopoulos • 26 Feb 2025
MEVPRO trials: investigating EZH2 inhibitors in mCRPC
0:41
MEVPRO trials: investigating EZH2 inhibitors in mCRPC
Michael Schweizer • 20 Feb 2025
ARTO: impact of BRCA status in abiraterone-treated mCRPC ± SBRT
1:14
ARTO: impact of BRCA status in abiraterone-treated mCRPC ± SBRT
Giulio Francolini • 18 Feb 2025
Neuroendocrine differentiation as a treatment target in prostate cancer
1:09
Neuroendocrine differentiation as a treatment target in prostate cancer
Cedric Pobel • 1 Nov 2024
PEACE-1: prognostic biomarkers in de novo metastatic prostate cancer
1:25
PEACE-1: prognostic biomarkers in de novo metastatic prostate cancer
Cedric Pobel • 24 Oct 2024
PEACE-1: abiraterone plus prednisone, ADT and docetaxel in mCSPC
0:44
PEACE-1: abiraterone plus prednisone, ADT and docetaxel in mCSPC
Cedric Pobel • 24 Sep 2024
CHAARTED2: cabazitaxel plus abiraterone vs. abiraterone alone for metastatic CRPC
2:07
CHAARTED2: cabazitaxel plus abiraterone vs. abiraterone alone for metastatic CRPC
Christos Kyriakopoulos • 7 Jun 2024
The potential role of luxdegalutamide, an oral PROTAC AR degrader, in mCRPC
0:35
The potential role of luxdegalutamide, an oral PROTAC AR degrader, in mCRPC
Daniel Petrylak • 4 Jun 2024
5-year follow up of short-course abiraterone and ADT for high-risk prostate cancer
1:38
5-year follow up of short-course abiraterone and ADT for high-risk prostate cancer
Andrew Armstrong • 22 May 2024
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nicholas James • 25 Apr 2024
The content of VJOncology is intended for healthcare professionals